Cargando…

Comparison of Chemotherapy Combined With Chidamide Versus Chemotherapy in the Frontline Treatment for Peripheral T-Cell Lymphoma

BACKGROUND: Peripheral T-cell lymphoma (PTCL) is featured with a poor survival outcome. China has approved chidamide, an oral novel histone deacetylase inhibitor, for patients diagnosed with relapsed or refractory PTCL. OBJECTIVE: We compared the benefit of traditional chemotherapy alone and a combi...

Descripción completa

Detalles Bibliográficos
Autores principales:	Wang, Jinni, Su, Ning, Fang, Yu, Ma, Shuyun, Zhang, Yuchen, Cai, Jun, Zou, Qihua, Tian, Xiaopeng, Xia, Yi, Liu, Panpan, Li, Zhiming, Huang, He, Huang, Huiqiang, Cai, Qingqing
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Frontiers Media S.A. 2022
Materias:	Immunology
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8847145/ https://www.ncbi.nlm.nih.gov/pubmed/35185926 http://dx.doi.org/10.3389/fimmu.2022.835103

Ejemplares similares

Comprehensive view on genetic features, therapeutic modalities and prognostic models in adult T-cell lymphoblastic lymphoma
por: Zou, Qihua, et al.
Publicado: (2022)

Chemotherapy Plus Radiotherapy Versus Chemotherapy Alone for Patients With Peripheral T-Cell Lymphoma, Not Otherwise Specified
por: Chen, Zegeng, et al.
Publicado: (2021)

Chidamide in the treatment of peripheral T-cell lymphoma
por: Chan, Thomas S, et al.
Publicado: (2017)

Efficacy and safety of anlotinib in metastatic adenoid cystic carcinoma: a retrospective study
por: Su, Ning, et al.
Publicado: (2022)

A Multi-Center, Real-World Study of Chidamide for Patients With Relapsed or Refractory Peripheral T-Cell Lymphomas in China
por: Liu, Weiping, et al.
Publicado: (2021)

Combination of anti-PD-1 antibody with P-GEMOX as a potentially effective immunochemotherapy for advanced natural killer/T cell lymphoma
por: Cai, Jun, et al.
Publicado: (2020)

Chidamide in relapsed or refractory peripheral T cell lymphoma: a multicenter real-world study in China
por: Shi, Yuankai, et al.
Publicado: (2017)

Chidamide combined with traditional chemotherapy for primary cutaneous aggressive epidermotropic CD8+ cytotoxic T-cell lymphoma: A case report
por: He, Zhen-Dong, et al.
Publicado: (2022)

Chidamide triggers BTG1-mediated autophagy and reverses the chemotherapy resistance in the relapsed/refractory B-cell lymphoma
por: Xue, Kai, et al.
Publicado: (2021)

Targeting P21-activated kinase suppresses proliferation and enhances chemosensitivity in T-cell lymphoblastic lymphoma
por: Su, Ning, et al.
Publicado: (2023)

Retrospective Analysis With Propensity Score Matching of Peripheral T-Cell Lymphoma Treated Frontline With Brentuximab Vedotin and Chemotherapy
por: Burke, John M, et al.
Publicado: (2023)

Chidamide combined with cyclophosphamide, doxorubicin, vincristine and prednisone in previously untreated patients with peripheral T-cell lymphoma
por: Gui, Lin, et al.
Publicado: (2021)

High-intensity chemotherapy improved the prognosis of patients with high-grade B-cell lymphoma
por: Chen, Yanfang, et al.
Publicado: (2022)

P1131: SERUM TRIGLYCERIDE AND APOLIPOPROTEIN A1 AS BIOMARKERS FOR EXTRANODAL NATURAL KILLER/T CELL LYMPHOMA (ENKTL): A MULTICENTER STUDY
por: Cai, Qingqing, et al.
Publicado: (2023)

P1237: HSF1 PROMOTES CHEMORESISTANCE IN DIFFUSE LARGE B-CELL LYMPHOMA VIA A PRMT5-DEPENDENT TRANSCRIPTIONAL PROGRAM HSF1通过PRMT5依赖性转录程序促进弥漫性大B细胞淋巴瘤的化疗耐药性
por: Cai, Qingqing, et al.
Publicado: (2023)

Chidamide plus prednisone, etoposide, and thalidomide for untreated angioimmunoblastic T‐cell lymphoma in a Chinese population: A multicenter phase II trial
por: Wang, Yawen, et al.
Publicado: (2022)

P1201: A REAL-WORLD STUDY OF CHIDAMIDE FOR PATIENTS WITH PERIPHERAL T-CELL LYMPHOMA IN CHINA
por: Wang, Xin, et al.
Publicado: (2023)

Ibrutinib as monotherapy versus combination therapy in Chinese patients with relapsed/refractory mantle cell lymphoma: A multicenter study
por: Zhang, Yuchen, et al.
Publicado: (2022)

Comparison between talazoparib and conventional chemotherapy in the treatment of HER2-positive breast cancer patients: A retrospective study
por: Wang, Ning, et al.
Publicado: (2022)

Zanubrutinib plus salvage chemotherapy for relapsed or refractory diffuse large B-cell lymphoma
por: Yuan, Xianggui, et al.
Publicado: (2022)

Preclinical Evaluation of the HDAC Inhibitor Chidamide in Transformed Follicular Lymphoma
por: Zhong, Mengya, et al.
Publicado: (2021)

Investigating Factors Associated with Thymic Regeneration after Chemotherapy in Patients with Lymphoma
por: Sun, Dao-Ping, et al.
Publicado: (2016)

Aberrant JAK-STAT signaling-mediated chromatin remodeling impairs the sensitivity of NK/T-cell lymphoma to chidamide
por: Chen, Jinghong, et al.
Publicado: (2023)

Modified R-CODOX-M/IVAC chemotherapy regimens in Chinese patients with untreated sporadic Burkitt lymphoma
por: Chen, Meiting, et al.
Publicado: (2021)

Sequential P‐GEMOX and radiotherapy for early‐stage extranodal natural killer/T‐cell lymphoma: A multicenter study
por: Zhang, Yuchen, et al.
Publicado: (2021)

Anlotinib as a third-line or further treatment for recurrent or metastatic nasopharyngeal carcinoma: a single-arm, phase 2 clinical trial
por: Fang, Yu, et al.
Publicado: (2023)

Neuroinflammatory Process Involved in Different Preclinical Models of Chemotherapy-Induced Peripheral Neuropathy
por: Fumagalli, Giulia, et al.
Publicado: (2021)

Neuroimmune Consequences of eIF4E Phosphorylation on Chemotherapy-Induced Peripheral Neuropathy
por: Agalave, Nilesh M., et al.
Publicado: (2021)

Moving at the frontline
por: Ataíde, Marco, et al.
Publicado: (2016)

Effect of chidamide on treating hepatosplenic T-cell lymphoma: A case report
por: Wang, Xing-Tong, et al.
Publicado: (2020)

Circulating PD‐1 (+) cells may participate in immune evasion in peripheral T‐cell lymphoma and chidamide enhance antitumor activity of PD‐1 (+) cells
por: Zhang, Wei, et al.
Publicado: (2019)

P1194: PROGNOSTIC SIGNIFICANCE OF SEQUENTIAL 18F-FDG PET/CT DURING THE TREATMENT OF ANTHRACYCLINE-CONTAINING FRONTLINE CHEMOTHERAPY IN PERIPHERAL T CELL LYMPHOMAS
por: Song, Ga-Young, et al.
Publicado: (2023)

Salmonella Immunotherapy Improves the Outcome of CHOP Chemotherapy in Non-Hodgkin Lymphoma-Bearing Mice
por: Bascuas, Thais, et al.
Publicado: (2018)

The Effect of Prophylactic Lamivudine plus Adefovir Therapy Compared with Lamivudine Alone in Preventing Hepatitis B Reactivation in Lymphoma Patients with High Baseline HBV DNA during Chemotherapy
por: Cai, Qingqing, et al.
Publicado: (2016)

P1172: ARTIFICIAL INTELLIGENCE FOR PROGNOSIS PREDICTION OF NATURAL KILLER/T-CELL LYMPHOMA BASED ON MAGNETIC RESONANCE IMAGING
por: Cai, Qingqing, et al.
Publicado: (2023)

Chidamide as maintenance after chemotherapy or hematopoietic stem cell transplantation in 27 children with T-cell lymphoblastic leukemia: A real-world prospective study
por: Li, Xin-Yu, et al.
Publicado: (2023)

Modified conditioning regimen with chidamide and high‐dose rituximab for triple‐hit lymphoma
por: Kang, Junnan, et al.
Publicado: (2021)

Efficacy of Frontline Chemotherapy for Extranodal Natural Killer/T-Cell Lymphoma: A Systematic Review and Network Meta-Analysis
por: Luo, Fei, et al.
Publicado: (2023)

Increased serum levels of interleukin-10 predict poor prognosis in extranodal natural killer/T-cell lymphoma patients receiving asparaginase-based chemotherapy
por: Wang, Hua, et al.
Publicado: (2015)

Chemotherapy-induced peripheral neuropathy
por: Zhang, Xia, et al.
Publicado: (2017)

Cannot write session to /tmp/vufind_sessions/sess_2llc29c2ic3it3n681kq6ve9o7